Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Buy Rating from Stifel Nicolaus
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “buy” rating reaffirmed by research analysts at Stifel Nicolaus in a report issued on Thursday. They currently have a $56.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $47.00. Stifel Nicolaus’ target price points to a potential downside of 26.26% from the company’s current price.
A number of other equities analysts have also recently issued reports on ALNY. Chardan Capital reiterated a “buy” rating and set a $124.00 price objective (down from $131.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. Sanford C. Bernstein began coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, July 27th. They set an “outperform” rating and a $99.00 price objective for the company. Barclays PLC upped their price objective on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, Morgan Stanley upped their price objective on shares of Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the stock an “equal weight” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $81.74.
Shares of Alnylam Pharmaceuticals (ALNY) traded down 5.69% during mid-day trading on Thursday, hitting $75.94. 2,078,084 shares of the company were exchanged. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $86.92. The firm’s market capitalization is $6.55 billion. The company’s 50-day moving average price is $81.35 and its 200-day moving average price is $61.53.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.12. The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.05) earnings per share. Equities research analysts predict that Alnylam Pharmaceuticals will post ($5.21) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/10/alnylam-pharmaceuticals-inc-nasdaqalny-receives-buy-rating-from-stifel-nicolaus.html.
In other news, VP Michael Mason sold 9,375 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total value of $656,250.00. Following the completion of the transaction, the vice president now owns 5,625 shares in the company, valued at $393,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Akshay Vaishnaw sold 43,750 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $65.00, for a total transaction of $2,843,750.00. Following the completion of the transaction, the senior vice president now owns 43,047 shares of the company’s stock, valued at approximately $2,798,055. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,125 shares of company stock valued at $4,325,000. 4.30% of the stock is currently owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in ALNY. First Manhattan Co. purchased a new position in Alnylam Pharmaceuticals during the first quarter worth approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $148,000. Westpac Banking Corp acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $202,000. Prudential Financial Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $215,000. Finally, CIBC Asset Management Inc acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $221,000. Institutional investors own 88.96% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.